- Home
- AGL vs EYPT Comparison
AGL vs EYPT Comparison
Compare AGL & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGL | EYPT |
|---|---|---|
| Founded | 2016 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2021 | 2005 |
Fundamental Metrics
Financial Performance| Metric | AGL | EYPT |
|---|---|---|
| Price | $106.03 | $12.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 5 |
| Target Price | ★ $55.68 | $31.80 |
| AVG Volume (30 Days) | 296.0K | ★ 901.4K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.94 | N/A |
| Revenue | ★ $5,932,576,000.00 | $7,539,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.23 | $3,115.57 |
| P/E Ratio | $34.75 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.30 | $8.37 |
| 52 Week High | $104.55 | $19.11 |
Technical Indicators
Market Signals| Indicator | AGL | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 76.31 | 43.23 |
| Support Level | $0.62 | $11.55 |
| Resistance Level | N/A | $12.24 |
| Average True Range (ATR) | 8.27 | 0.74 |
| MACD | -0.50 | -0.08 |
| Stochastic Oscillator | 88.05 | 32.60 |
Price Performance
Historical ComparisonAbout AGL agilon health inc.
Agilon Health Inc is a healthcare services company that partners with primary care physicians to support value-based care for senior patients. The company provides a platform that enables physician groups to manage healthcare outcomes and costs through a Medicare-centric, capitated care model and long-term partnerships with community-based physicians.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.